Here are the latest G-BA decisions from the G-BA meeting held on 2 Oct 2024 on the early benefit assessments of Velsipity, Eladynos, Altuvoct and Ryzneuta.
A complete database of all previous G-BA resolutions is in my membership.
This time, the G-BA met on a Wednesday and made the following decisions. Interestingly, for two products, Altuvoct and Ryzneuta, no dossier was submitted, and the G-BA immediately included these in a reference price group. Since 2011 and the beginning of benefit assessments, this has happened only 8 times.
- Velsipity (etrasimod); ulcerative colitis, previously treated, ≥ 16 years – Additional benefit not proven in both subgroups
- Eladynos (abaloparatide); osteoporosis, postmenopausal women – Additional benefit not proven, time restricted until 1 April 2025
- Altuvoct (efanesoctocog alfa); haemophilia A – orphan drug, due to non-submission of a dossier, an additional benefit is deemed not to be proven; thus, the drug is classified in the reference price group with pharmacologically and therapeutically comparable drugs
- Ryzneuta (efbemalenograstim alfa); febrile neutropenia due to chemotherapy – due to non-submission of a dossier, an additional benefit is deemed not to be proven; thus, the drug is classified in the reference price group with pharmacologically and therapeutically comparable drugs
Follow me on Instagram to never miss the latest G-BA decisions: